Asian Spectator


The Times

.

Guangdong Goods Go Global Promotional Video Released, Extending an Invitation to the World from Guangdong

SHENZHEN, CHINA – Media OutReach Newswire – 18 November 2026 – On November 18–19, the 33rd APEC Economic Leaders' Meeting kicks off in Shenzhen, drawing global attention to Gu...

DFA Awards 2019 Winners Announcement

A showcase of design excellence in Asia HONG KONG, CHINA - Media OutReach - 30 October 2019 - DFA Awards2019 celebrates established and emerging designers that push creat...

Laserfiche Recognized as a Strong Performer in Independent Ana...

LONG BEACH, Calif., June 15, 2021 /PRNewswire-AsiaNet/ -- Laserfiche ( https://c212.net/c/link/?t=0&l=en&o=3196206-1&h=3762804764&u=https%3A%2F%2Fwww.laserfiche.com%2F%3Futm_...

Toyota Group Key Supplier JTEKT Commissions 2,500 MWh Solar Carport in Kagawa Under 20-Year PPA with Peak Energy

Commissioning reflects Japan manufacturers’ shift to site-level renewables under long-term PPAs amid tighter group decarbonisation expectations and unstable energy costs.TOKYO, JAPAN -...

The IFF 2021 Annual Meeting Targets Strengthening Global Susta...

GUANGZHOU, China, Nov. 29, 2021 /PRNewswire-AsiaNet/ -- Themed "Sustainable Development under Global Challenges: Competition, Change and Cooperation", the International Finance Forum (IFF) t...

5 well-kept secrets of professional traders according to Octa

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 5 July 2024 - Trading in the global markets, especially Forex, is sometimes perceived as a game of luck by those who don't know much about...

Gold's road to $3,000: expert analysis by global broker Octa

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 5 December 2024 - Gold has been valued for its stability when the financial fires are raging. That stable nature was underscored in 2024 w...

Gold’s Path to $4,000: Macro Drivers, Market Sentiment, and Strategic Insight by global broker Octa

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 30 April 2025 - Gold has kept on rising almost uninterruptedly for most of 2025, recording a series of new all-time highs. Since October 2...

HONOR Sets Sights on Doubling Global Sales in 2022, Reaffirms ...

SHENZHEN, China, March 4, 2022 / PRNewswire-AsiaNet / -- CEO of HONOR outlines his plans to focus efforts on delivering new innovations and user experiences for consumers in key global marke...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/casino siteleriStreamEastStreamEastjojobetcialis 20 mg fiyat